Related Experiment Video

Updated: Aug 19, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Raf kinase inhibitors in oncology

Dirk Strumberg1, Siegfried Seeber

  • 1Department of Internal Medicine and Medical Oncology, West German Cancer Center, University of Essen, Germany. dirk.strumberg@uni-essen.de

Onkologie
|January 25, 2005
PubMed

Insights

Targeting the Raf kinase pathway, including Raf, MEK1/2, and ERK1/2, shows therapeutic potential for tumors with BRAF mutations. Raf inhibitors demonstrate anti-cancer efficacy and a tolerable safety profile in clinical evaluations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The MAP kinase pathway, comprising Raf, MEK1/2, and ERK1/2, is crucial for tumor cell proliferation and survival.
  • Activating BRAF mutations in human tumors highlight the therapeutic potential of targeting this pathway.

Purpose of the Study:

  • To review the rationale for targeting Raf kinase in cancer treatment.
  • To summarize the current status of pharmacological approaches, including Raf inhibitors.

Main Methods:

  • Review of scientific literature on the MAP kinase pathway and Raf inhibitors.
  • Analysis of preclinical and clinical data for Raf-targeting agents.

Main Results:

  • Raf inhibitors can prevent Raf protein expression, block Ras/Raf interaction, or inhibit kinase activity.
  • Clinically evaluated Raf inhibitors show promising anti-cancer efficacy with good safety profiles.
  • BAY 43-9006 is the most advanced Raf inhibitor, currently in phase III clinical trials.

Conclusions:

  • Targeting the Raf kinase pathway is a viable strategy for treating tumors with BRAF oncogenes.
  • Pharmacological inhibition of Raf kinase offers a promising therapeutic avenue with a favorable safety profile.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...